14,310$
-1,85%
Echtzeit-Aktienkurs IGM Biosciences Inc.
Bid:
Ask:
Echtzeit-Chart der IGM Biosciences Inc. Aktie
Börsenkurse IGM Biosciences Inc.
| gettex | - | - | - | - | 13,400€ | 1,13% |
| Lang & Schwarz | - | - | - | - | 13,350€ | 0,38% |
| Echtzeit USD | - | - | - | - | 14,332$ | -0,26% |
| Echtzeit Euro | - | - | - | - | 13,350€ | -2,55% |
| USA | - | - | - | - | 14,370$ | -1,30% |
| Börse Frankfurt | - | - | - | - | 13,400€ | -2,19% |
| Börse Stuttgart | - | - | - | - | 13,350€ | 0,38% |
| New York | - | - | - | - | - | - |
| Nasdaq | - | - | - | - | 14,310$ | -1,85% |
Fundamentaldaten der IGM Biosciences Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 2,13 Mio. | -245,74 Mio. | -246,42 Mio. | -4,71 | - | - | 394,24 |
| 2022 [USD] | 1,07 Mio. | -221,10 Mio. | -221,10 Mio. | -5,32 | - | - | 576,71 |
| 2021 [USD] | - | -165,16 Mio. | -165,16 Mio. | -4,93 | - | - | - |
| 2020 [USD] | - | -81,36 Mio. | -81,36 Mio. | -2,65 | - | - | - |
| 2019 [USD] | - | -43,13 Mio. | -43,13 Mio. | -4,80 | - | - | - |
| 2018 [USD] | - | -22,71 Mio. | -22,71 Mio. | -0,74 | - | - | - |
| 2017 [USD] | - | -11,05 Mio. | -11,05 Mio. | -0,36 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der IGM Biosciences Inc. Aktie
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.